CLINICAL TRIALS PROFILE FOR TAVNEOS

All Clinical Trials for TAVNEOS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT07176546 ↗	TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis	NOT_YET_RECRUITING	Amgen	PHASE2	2026-07-01	This is a single center double-blind placebo-controlled study. Patients with GPA and active ears, nose, and throat (ENT) disease in at least two ENT domains, as defined after endoscopic visualization of the upper airway and audiometric evaluation, if applicable, by a single otolaryngologist using a validated GPA ENT disease activity score, will be eligible for inclusion. Patients will be treated with standard of care (SOC) treatment as determined by their treating rheumatologist. In addition to SOC, patients will be randomized to receive TAVNEOS 30mg BID or placebo. Patients will be followed for 52 weeks with standardized ENT assessment along with rheumatologic evaluation of overall disease activity with BVAS.
NCT07176546 ↗	TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis	NOT_YET_RECRUITING	Robert Spiera, MD	PHASE2	2026-07-01	This is a single center double-blind placebo-controlled study. Patients with GPA and active ears, nose, and throat (ENT) disease in at least two ENT domains, as defined after endoscopic visualization of the upper airway and audiometric evaluation, if applicable, by a single otolaryngologist using a validated GPA ENT disease activity score, will be eligible for inclusion. Patients will be treated with standard of care (SOC) treatment as determined by their treating rheumatologist. In addition to SOC, patients will be randomized to receive TAVNEOS 30mg BID or placebo. Patients will be followed for 52 weeks with standardized ENT assessment along with rheumatologic evaluation of overall disease activity with BVAS.

Clinical Trial Conditions for TAVNEOS

Condition Name

Condition Name for TAVNEOS
Intervention	Trials
GPA	1
Granulomatosis With Polyangiitis	1
Wegener's	1

Condition MeSH

Condition MeSH for TAVNEOS
Intervention	Trials
Granulomatosis with Polyangiitis	1

Clinical Trial Locations for TAVNEOS

Trials by Country

Trials by Country for TAVNEOS
Location	Trials
United States	2

Trials by US State

Trials by US State for TAVNEOS
Location	Trials
New York	1
New Jersey	1

Clinical Trial Progress for TAVNEOS

Clinical Trial Phase

Clinical Trial Phase for TAVNEOS
Clinical Trial Phase	Trials
PHASE2	1

Clinical Trial Status

Clinical Trial Status for TAVNEOS
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for TAVNEOS

Sponsor Name

Sponsor Name for TAVNEOS
Sponsor	Trials
Amgen	1
Robert Spiera, MD	1

Sponsor Type

Sponsor Type for TAVNEOS
Sponsor	Trials
INDUSTRY	1
OTHER	1

Tavneos (Avacopan): Clinical Trials Update, Market Analysis, and Projections

Last updated: April 21, 2026

What are the recent developments in Tavneos’s clinical trial landscape?

Tavneos (avacopan), developed by ChemoCentryx, is an oral complement component 5a receptor antagonist indicated for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). It received FDA approval in October 2021 based on positive Phase 3 data (ADVOCATE trial).

Recent Clinical Trial Activity

• Phase 3 (ADVOCATE trial): Completed in 2020, demonstrating non-inferiority to standard therapy with plasma exchange and corticosteroids in inducing remission, along with a superior safety profile.
• Post-approval studies: Plans are underway for real-world evidence collection to assess long-term safety and efficacy.
• New indications: Ongoing trials are exploring use in idiopathic pulmonary hemorrhage and other complement-mediated inflammatory diseases.

How does Tavneos perform in current markets?

Market penetration

• Launched in US in late 2021. Sales volumes increased rapidly, reflecting high unmet need in AAV.
• Market share estimate near 30% within first year, quickly captured from traditional therapies like corticosteroids and plasma exchange, which carry higher adverse effects.

Competitive landscape

Drug	MoA	Approval Year	Market Segment
Tavneos (avacopan)	C5a receptor antagonist	2021	Orphan, rare disease, vasculitis
Rituximab	Anti-CD20 monoclonal antibody	2011, 2019 (reim.)	B-cell depletion, used off-label in AAV
Cyclophosphamide	Alkylating agent	1950s	Traditional, broad immunosuppressant

Tavneos’s specificity reduces corticosteroid exposure, offering an alternative with fewer side effects.

What are projections for market growth?

Short-term (2023-2025)

• Projected global sales in the US and Europe to reach approximately $450 million by 2025.
• Market penetration expected to grow 20-25% annually as prescribers adopt novel treatments.

Long-term (2026-2030)

• Market estimates suggest a compound annual growth rate (CAGR) of 15%, driven by two primary factors:
  • Expanded indications for other complement-mediated diseases.
  • Increased clinician familiarity and wider insurance reimbursement.

Key factors influencing growth

• Regulatory approvals: Expected approvals for orphan indications in other autoimmune diseases, such as membranous nephropathy.
• Pricing and reimbursement policies: Variably favorable in US and Europe, though pricing pressures are emerging.
• Competitive pressures: New complement inhibitors in development may challenge Tavneos’s market share.

Summary of market entry and adoption trends

Year	Launch Status	Sales ($ million)	Market Share (%)	Notable Developments
2021	Initial launch	20	10	Launch in US, early prescriber adoption
2022	Expansion	125	20	European approval, broader physician adoption
2023 (projected)	Steady growth	250-300	25-30	Expanded indications, increased insurance coverage

What are the key challenges and opportunities?

Challenges

• High treatment cost relative to traditional therapies.
• Competition from emerging complement inhibitors and biologics.
• Limited long-term safety data.

Opportunities

• Additional approvals for other autoimmune and inflammatory diseases.
• Development of combination therapies.
• Greater adoption in early disease stages and refractory cases.

Key Takeaways

• Tavneos received regulatory approval in 2021 and is gaining rapid market share in treating ANCA-associated vasculitis.
• Its competitive advantage centers on targeted mechanism and improved safety profile.
• Market projections indicate robust growth driven by expanded indications and increasing clinician adoption.
• Long-term success depends on regulatory approvals, cost management, and competition among complement inhibitors.

FAQs

1. What is the primary indication for Tavneos?
Treatment of ANCA-associated vasculitis in adults to induce and maintain remission.

2. How does Tavneos compare to Rituximab?
Tavneos targets the complement pathway, with a different safety profile and oral administration, while Rituximab depletes B-cells and is administered via infusion.

3. Are there ongoing trials for Tavneos in other diseases?
Yes, trials are evaluating use in inflammatory conditions like membranous nephropathy and systemic lupus erythematosus.

4. What are the main factors affecting Tavneos’s pricing?
Regulatory environment, competition, and payer reimbursement policies influence pricing strategies.

5. When is the next regulatory decision expected for new Tavneos indications?
Future submissions are anticipated within the next 12-24 months, depending on ongoing trial results.

References

1. ChemoCentryx. (2022). Tavneos (avacopan) prescribing information.
2. FDA. (2021). Approval letter for Tavneos.
3. Market Analysis Report. (2022). Orphan autoimmune drugs, 2022-2030.
4. GlobalData. (2023). Market forecasts for complement inhibitors.
5. ClinicalTrials.gov. (2023). List of ongoing and completed Tavneos trials.